Atlas Trials

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Clinical trial NCT03132181 · COMPLETED

Trial details

NCT number
NCT03132181
Sponsor
RWTH Aachen University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diabetes Mellitus Type 2 (T2DM)
Start date
2017-04-24
Primary completion
2019-01-23
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.